» Articles » PMID: 38250460

Liver Lesions at Risk of Transformation into Hepatocellular Carcinoma in Cirrhotic Patients: Hepatobiliary Phase Hypointense Nodules Without Arterial Phase Hyperenhancement

Overview
Specialty Gastroenterology
Date 2024 Jan 22
PMID 38250460
Authors
Affiliations
Soon will be listed here.
Abstract

Recent technical advances in liver imaging and surveillance for patients at high risk for developing hepatocellular carcinoma (HCC) have led to an increase in the detection of borderline hepatic nodules in the gray area of multistep carcinogenesis, particularly in those that are hypointense at the hepatobiliary phase (HBP) and do not show arterial phase hyperenhancement. Given their potential to transform and advance into hypervascular HCC, these nodules have progressively attracted the interest of the scientific community. To date, however, no shared guidelines have been established for the decision management of these borderline hepatic nodules. It is therefore extremely important to identify features that indicate the malignant potential of these nodules and the likelihood of vascularization. In fact, a more complete knowledge of their history and evolution would allow outlining shared guidelines for their clinical-surgical management, to implement early treatment programs and decide between a preventive curative treatment or a watchful follow-up. This review aims to summarize the current knowledge on hepatic borderline nodules, particularly focusing on those imaging features which are hypothetically correlated with their malignant evolution, and to discuss current guidelines and ongoing management in clinical practice.

Citing Articles

Hepatobiliary-Phase Hypointense Nodules Without Arterial-Phase Hyperenhancement: Developing a Risk Stratification for Hypervascular Transformation Based on a Real-World Observational Cohort Study.

Li N, Wang Y, Yang L, Yang C, Zeng M Technol Cancer Res Treat. 2024; 23:15330338241299003.

PMID: 39544080 PMC: 11565688. DOI: 10.1177/15330338241299003.


Risk of Malignancy in Indeterminate Liver Nodules Among Patients with Cirrhosis: A Retrospective Cohort Study.

Yahia Y, Qasem M, Abbarh S, Saffo H, Obeidat I, Barjas H J Gastrointest Cancer. 2024; 56(1):1.

PMID: 39414724 PMC: 11485135. DOI: 10.1007/s12029-024-01122-7.

References
1.
Ohtomo K, BARON R, Dodd 3rd G, Federle M, Ohtomo Y, Confer S . Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology. 1993; 189(3):871-4. DOI: 10.1148/radiology.189.3.8234718. View

2.
Li J, Wang J, Lei L, Yuan G, He S . The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. Eur Radiol. 2019; 29(12):6519-6528. DOI: 10.1007/s00330-019-06294-6. View

3.
Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M . Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol. 2012; 30(9):743-51. DOI: 10.1007/s11604-012-0120-5. View

4.
Li X, Li C, Wang R, Ren J, Yang J, Zhang Y . Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis. PLoS One. 2015; 10(12):e0144247. PMC: 4668097. DOI: 10.1371/journal.pone.0144247. View

5.
Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y . Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with.... Invest Radiol. 2010; 45(3):133-41. DOI: 10.1097/RLI.0b013e3181caea5b. View